CY1123325T1 - Κυτταροτοξικα παραγωγα βενζοδιαζεπινης - Google Patents
Κυτταροτοξικα παραγωγα βενζοδιαζεπινηςInfo
- Publication number
- CY1123325T1 CY1123325T1 CY20201100835T CY201100835T CY1123325T1 CY 1123325 T1 CY1123325 T1 CY 1123325T1 CY 20201100835 T CY20201100835 T CY 20201100835T CY 201100835 T CY201100835 T CY 201100835T CY 1123325 T1 CY1123325 T1 CY 1123325T1
- Authority
- CY
- Cyprus
- Prior art keywords
- benzodiazepine derivatives
- compounds
- conjugates
- cytotoxic benzodiazepine
- benzodiazepine
- Prior art date
Links
- 229940053197 benzodiazepine derivative antiepileptics Drugs 0.000 title abstract 2
- 150000001557 benzodiazepines Chemical class 0.000 title 1
- 231100000433 cytotoxic Toxicity 0.000 title 1
- 230000001472 cytotoxic effect Effects 0.000 title 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
Abstract
Η εφεύρεση αφορά νέα παράγωγα βενζοδιαζεπίνης με αντιπολλαπλασιαστική δραστικότητα και πλέον συγκεκριμένα νέες ενώσεις βενζοδιαζεπίνης του τύπου (I)-(VI). Η εφεύρεση παρέχει επίσης συζεύγματα των ενώσεων βενζοδιαζεπίνης συνδεδεμένα με έναν παράγοντα δέσμευσης κυττάρων. Η εφεύρεση παρέχει περαιτέρω συνθέσεις και μεθόδους χρήσιμες για την αναστολή μη φυσιολογικής κυτταρικής αύξηση ή θεραπεία μιας πολλαπλασιαστικής διαταραχής σε ένα θηλαστικό με τη χρήση των ενώσεων ή συζευγμάτων της εφεύρεσης.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462045248P | 2014-09-03 | 2014-09-03 | |
US201462087040P | 2014-12-03 | 2014-12-03 | |
US201562149370P | 2015-04-17 | 2015-04-17 | |
US201562164305P | 2015-05-20 | 2015-05-20 | |
PCT/US2015/048059 WO2016036801A1 (en) | 2014-09-03 | 2015-09-02 | Cytotoxic benzodiazepine derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1123325T1 true CY1123325T1 (el) | 2021-12-31 |
Family
ID=54140691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20201100835T CY1123325T1 (el) | 2014-09-03 | 2020-09-04 | Κυτταροτοξικα παραγωγα βενζοδιαζεπινης |
Country Status (32)
Country | Link |
---|---|
US (5) | US9669102B2 (el) |
EP (2) | EP3778601A1 (el) |
JP (4) | JP6606545B2 (el) |
KR (2) | KR20240023671A (el) |
CN (2) | CN116514903A (el) |
AU (3) | AU2015311987B2 (el) |
BR (1) | BR112017002963A2 (el) |
CA (1) | CA2959630A1 (el) |
CL (1) | CL2017000507A1 (el) |
CO (1) | CO2017003011A2 (el) |
CR (1) | CR20170111A (el) |
CY (1) | CY1123325T1 (el) |
DK (1) | DK3189056T3 (el) |
DO (1) | DOP2017000053A (el) |
EA (1) | EA034138B1 (el) |
EC (1) | ECSP17020133A (el) |
ES (1) | ES2815353T3 (el) |
HU (1) | HUE051002T2 (el) |
IL (4) | IL250712B (el) |
LT (1) | LT3189056T (el) |
MA (1) | MA54254A (el) |
MX (1) | MX2017002758A (el) |
PE (1) | PE20170775A1 (el) |
PH (1) | PH12017500358A1 (el) |
PL (1) | PL3189056T3 (el) |
PT (1) | PT3189056T (el) |
RS (1) | RS60751B1 (el) |
SG (2) | SG11201701455SA (el) |
SI (1) | SI3189056T1 (el) |
TN (1) | TN2017000070A1 (el) |
TW (4) | TWI819474B (el) |
WO (1) | WO2016036801A1 (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016036861A1 (en) | 2014-09-02 | 2016-03-10 | Immunogen, Inc. | Methods for formulating antibody drug conjugate compositions |
LT3189056T (lt) * | 2014-09-03 | 2020-09-25 | Immunogen, Inc. | Citotoksiniai benzodiazepinai |
EP3313884B9 (en) * | 2015-06-29 | 2021-05-19 | ImmunoGen, Inc. | Anti-cd123 antibodies and conjugates and derivatives thereof |
SG10202106529XA (en) * | 2015-07-21 | 2021-07-29 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
DK3380525T3 (da) | 2015-11-25 | 2024-01-29 | Immunogen Inc | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf |
EA201891723A1 (ru) * | 2016-02-05 | 2018-12-28 | Милленниум Фармасьютикалз, Инк. | Gcc-направленные конъюгаты антитело-лекарство |
KR20230133935A (ko) | 2016-11-23 | 2023-09-19 | 이뮤노젠 아이엔씨 | 벤조다이아제핀 유도체의 선택적인 설폰화 |
TWI783957B (zh) | 2016-12-23 | 2022-11-21 | 美商伊繆諾金公司 | 靶向adam9之免疫共軛物及其使用方法 |
TW201825515A (zh) | 2017-01-04 | 2018-07-16 | 美商伊繆諾金公司 | Met抗體以及其免疫結合物及用途 |
WO2018183494A1 (en) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
CN110573510B (zh) | 2017-04-20 | 2022-10-11 | 伊缪诺金公司 | 制备吲哚啉并苯并二氮杂䓬衍生物的方法 |
US11638760B2 (en) | 2017-11-27 | 2023-05-02 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
JP2021506883A (ja) | 2017-12-21 | 2021-02-22 | メルサナ セラピューティクス インコーポレイテッド | ピロロベンゾジアゼピン抗体結合体 |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
TW202102270A (zh) * | 2019-03-21 | 2021-01-16 | 美商伊繆諾金公司 | 製備細胞結合劑-藥物結合物之方法 |
BR112021017350A2 (pt) * | 2019-03-27 | 2021-11-16 | Daiichi Sankyo Co Ltd | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp |
AU2020347257A1 (en) | 2019-09-13 | 2022-04-28 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3453266A (en) | 1966-03-14 | 1969-07-01 | American Home Prod | 1,2,5-benzothiadiazepine 1,1-dioxides |
US3506646A (en) | 1966-06-27 | 1970-04-14 | American Home Prod | Process for the preparation of 7h-pyrido (1,2-b)(1,2,5)benzothiadiazepine 5,5 - dioxides and pyrrolo(1,2-b)(1,2,5)benzothiadiazepine 5,5-dioxides |
US3875162A (en) | 1973-07-26 | 1975-04-01 | Squibb & Sons Inc | Certain 6H-pyrimido{8 1,2-c{9 {8 1,3,5{9 benzothiadiaza compounds |
US4003905A (en) | 1974-12-11 | 1977-01-18 | E. R. Squibb & Sons, Inc. | Diels-alder adducts of benzdiazepines |
US4444688A (en) | 1981-05-11 | 1984-04-24 | Ciba-Geigy Corporation | Imidazobenzothiadiazepines |
JP2920385B2 (ja) | 1988-08-18 | 1999-07-19 | 武田薬品工業株式会社 | 1,2,5‐ベンゾチアジアゼピン誘導体,その製造法および用途 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US20080152586A1 (en) | 1992-09-25 | 2008-06-26 | Avipep Pty Limited | High avidity polyvalent and polyspecific reagents |
US6355780B1 (en) | 1995-02-22 | 2002-03-12 | Yeda Research And Development Co. Ltd. | Antibodies to the death domain motifs of regulatory proteins |
CA2297070A1 (en) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex |
US6156746A (en) | 1998-08-25 | 2000-12-05 | Bristol-Myers Squibb Company | 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents |
PT1109812E (pt) | 1998-08-27 | 2005-09-30 | Spirogen Ltd | Pirrolobenzodiazepinas |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
EP1242401B1 (en) | 1999-11-24 | 2006-12-27 | Immunogen, Inc. | Cytotoxic agents comprising taxanes and their therapeutic use |
WO2002020565A2 (en) | 2000-09-08 | 2002-03-14 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
GB0209467D0 (en) | 2002-04-25 | 2002-06-05 | Astrazeneca Ab | Chemical compounds |
BR0313197A (pt) | 2002-08-02 | 2005-08-09 | Immunogen Inc | Agentes citotóxicos contendo potentes taxanos e seu uso terapêutico |
JP2006500364A (ja) | 2002-08-16 | 2006-01-05 | イムノージェン インコーポレーテッド | 高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用 |
EA010570B1 (ru) | 2002-11-07 | 2008-10-30 | Иммьюноджен, Инк. | Антитело к cd33 и способы его применения |
FR2850654A1 (fr) | 2003-02-03 | 2004-08-06 | Servier Lab | Nouveaux derives d'azepines tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
SI3524611T1 (sl) | 2003-05-20 | 2021-05-31 | Immunogen, Inc. | Izboljšana citotoksična sredstva, ki vsebujejo nove majtanzinoide |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
DK1660513T5 (da) | 2003-07-21 | 2011-07-18 | Immunogen Inc | CA6 antigen-specifikt, cytotoksisk konjugat og fremgangsmåder til anvendelse heraf |
EP1675857B1 (en) * | 2003-10-22 | 2011-07-13 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto |
JP5166861B2 (ja) | 2004-03-09 | 2013-03-21 | スピロゲン リミティッド | ピロロベンゾジアゼピン |
CA2564251C (en) | 2004-05-21 | 2018-04-10 | The Uab Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
CA2567520A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Maytansinoid-antibody conjugates |
EP3088004B1 (en) | 2004-09-23 | 2018-03-28 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP1817341A2 (en) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
JP5165387B2 (ja) | 2005-02-11 | 2013-03-21 | イムノゲン インコーポレーティッド | 安定な薬物複合体を調製するための方法 |
PL1902131T3 (pl) | 2005-07-08 | 2010-05-31 | Univ Zuerich | Prezentacja fagowa z zastosowaniem kotranslacyjnej translokacji polipeptydów fuzyjnych |
US7772485B2 (en) | 2005-07-14 | 2010-08-10 | Konarka Technologies, Inc. | Polymers with low band gaps and high charge mobility |
ITRM20050416A1 (it) | 2005-08-03 | 2007-02-04 | Uni Degli Studi Di Roma Tor Vergata | Derivati delle benzodiazepine e loro usi in campo medico. |
CN101242855A (zh) | 2005-08-22 | 2008-08-13 | 伊缪诺金公司 | Ca6抗原特异性细胞毒性偶联物及其应用方法 |
PL1928503T3 (pl) | 2005-08-24 | 2012-12-31 | Immunogen Inc | Sposób wytwarzania koniugatów majtazynoid-przeciwciało |
US8623356B2 (en) | 2005-11-29 | 2014-01-07 | The University Of Sydney | Demibodies: dimerization-activated therapeutic agents |
DK1813614T3 (da) | 2006-01-25 | 2012-01-23 | Sanofi Sa | Cytotoksiske midler, der omfatter nye tomaymycinderivater |
US7897568B2 (en) | 2006-03-03 | 2011-03-01 | Vinay K. Singh | Compositions for treatment of cancer |
CN103030696B (zh) | 2006-05-30 | 2016-09-28 | 健泰科生物技术公司 | 抗体和免疫偶联物及其用途 |
WO2007147213A1 (en) | 2006-06-22 | 2007-12-27 | Walter And Eliza Hall Institute Of Medical Research | Structure of the insulin receptor ectodomain |
SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
US9365629B2 (en) | 2007-09-24 | 2016-06-14 | University Of Zurich | Designed armadillo repeat proteins |
KR20100137585A (ko) | 2008-04-30 | 2010-12-30 | 이뮤노젠 아이엔씨 | 강력한 복합체 및 친수성 링커 |
KR101892411B1 (ko) | 2008-04-30 | 2018-08-27 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
HUE030471T2 (en) | 2008-10-31 | 2017-05-29 | Janssen Biotech Inc | III. fibronectin-based framework products, methods and applications |
MX368362B (es) | 2009-02-05 | 2019-09-30 | Immunogen Inc | Derivados novedosos de benzodiacepina. |
CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
FR2947269B1 (fr) * | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
JP2013514788A (ja) | 2009-12-23 | 2013-05-02 | アビペップ ピーティーワイ リミテッド | イムノコンジュゲート及びその作製方法2 |
DK2538976T3 (en) | 2010-02-24 | 2017-02-27 | Immunogen Inc | IMMUNCONJUGATES AGAINST FOLATRECEPTOR-1 AND APPLICATIONS THEREOF |
PT2544719T (pt) | 2010-03-12 | 2019-10-17 | Debiopharm Int Sa | Moléculas de ligação a cd37 e imunoconjugados das mesmas |
EP2571531B1 (en) | 2010-04-30 | 2016-06-22 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
CN103328505B (zh) | 2010-10-29 | 2015-12-02 | 伊缪诺金公司 | 非拮抗性egfr结合分子及其免疫偶联物 |
CN103298489A (zh) | 2010-10-29 | 2013-09-11 | 伊缪诺金公司 | 新型egfr结合分子及其免疫偶联物 |
EP3666289A1 (en) * | 2011-02-15 | 2020-06-17 | ImmunoGen, Inc. | Cytotoxic benzodiazepine derivatives |
IL281714B2 (en) | 2011-04-01 | 2023-11-01 | Immunogen Inc | Methods for increasing the effectiveness of FOLR1 cancer therapy |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
SI2917195T1 (en) * | 2012-11-05 | 2018-04-30 | Pfizer Inc. | Spliceostatin analogues |
SG10201901825YA (en) * | 2014-09-03 | 2019-03-28 | Immunogen Inc | Conjugates comprising cell-binding agents and cytotoxic agents |
LT3189056T (lt) | 2014-09-03 | 2020-09-25 | Immunogen, Inc. | Citotoksiniai benzodiazepinai |
-
2015
- 2015-09-02 LT LTEP15763739.8T patent/LT3189056T/lt unknown
- 2015-09-02 CN CN202210858832.1A patent/CN116514903A/zh active Pending
- 2015-09-02 TW TW111102997A patent/TWI819474B/zh active
- 2015-09-02 MA MA054254A patent/MA54254A/fr unknown
- 2015-09-02 TN TN2017000070A patent/TN2017000070A1/en unknown
- 2015-09-02 JP JP2017512775A patent/JP6606545B2/ja active Active
- 2015-09-02 PT PT157637398T patent/PT3189056T/pt unknown
- 2015-09-02 PE PE2017000378A patent/PE20170775A1/es unknown
- 2015-09-02 PL PL15763739T patent/PL3189056T3/pl unknown
- 2015-09-02 KR KR1020247003505A patent/KR20240023671A/ko active Application Filing
- 2015-09-02 HU HUE15763739A patent/HUE051002T2/hu unknown
- 2015-09-02 CA CA2959630A patent/CA2959630A1/en active Pending
- 2015-09-02 CN CN201580047847.8A patent/CN106604927B/zh active Active
- 2015-09-02 EP EP20178715.7A patent/EP3778601A1/en active Pending
- 2015-09-02 MX MX2017002758A patent/MX2017002758A/es unknown
- 2015-09-02 AU AU2015311987A patent/AU2015311987B2/en active Active
- 2015-09-02 SG SG11201701455SA patent/SG11201701455SA/en unknown
- 2015-09-02 KR KR1020177009021A patent/KR102632830B1/ko active IP Right Grant
- 2015-09-02 TW TW109118465A patent/TWI757759B/zh active
- 2015-09-02 EP EP15763739.8A patent/EP3189056B1/en active Active
- 2015-09-02 RS RS20201000A patent/RS60751B1/sr unknown
- 2015-09-02 ES ES15763739T patent/ES2815353T3/es active Active
- 2015-09-02 DK DK15763739.8T patent/DK3189056T3/da active
- 2015-09-02 EA EA201790446A patent/EA034138B1/ru unknown
- 2015-09-02 TW TW112135631A patent/TW202417447A/zh unknown
- 2015-09-02 US US14/843,520 patent/US9669102B2/en active Active
- 2015-09-02 SG SG10201901824UA patent/SG10201901824UA/en unknown
- 2015-09-02 SI SI201531320T patent/SI3189056T1/sl unknown
- 2015-09-02 CR CR20170111A patent/CR20170111A/es unknown
- 2015-09-02 WO PCT/US2015/048059 patent/WO2016036801A1/en active Application Filing
- 2015-09-02 BR BR112017002963A patent/BR112017002963A2/pt not_active Application Discontinuation
- 2015-09-02 TW TW104128985A patent/TWI697493B/zh active
-
2017
- 2017-02-22 IL IL250712A patent/IL250712B/en active IP Right Grant
- 2017-02-28 PH PH12017500358A patent/PH12017500358A1/en unknown
- 2017-03-02 DO DO2017000053A patent/DOP2017000053A/es unknown
- 2017-03-03 CL CL2017000507A patent/CL2017000507A1/es unknown
- 2017-03-28 CO CONC2017/0003011A patent/CO2017003011A2/es unknown
- 2017-04-03 EC ECIEPI201720133A patent/ECSP17020133A/es unknown
- 2017-04-28 US US15/581,749 patent/US10238751B2/en active Active
-
2019
- 2019-02-13 US US16/274,665 patent/US10722588B2/en active Active
- 2019-10-21 JP JP2019192174A patent/JP6802340B2/ja active Active
-
2020
- 2020-04-21 IL IL281317A patent/IL281317B/en unknown
- 2020-04-21 IL IL274114A patent/IL274114A/en unknown
- 2020-06-15 US US16/901,754 patent/US11116845B2/en active Active
- 2020-08-31 AU AU2020227006A patent/AU2020227006B2/en active Active
- 2020-09-04 CY CY20201100835T patent/CY1123325T1/el unknown
- 2020-11-26 JP JP2020195666A patent/JP7132311B2/ja active Active
-
2022
- 2022-03-22 IL IL291598A patent/IL291598A/en unknown
- 2022-04-12 AU AU2022202418A patent/AU2022202418B2/en active Active
- 2022-08-24 JP JP2022133442A patent/JP2022166293A/ja active Pending
- 2022-10-25 US US17/973,209 patent/US20230233697A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1123325T1 (el) | Κυτταροτοξικα παραγωγα βενζοδιαζεπινης | |
CY1117340T1 (el) | Κυτταροτοξικα παραγωγα βενζοδιαζεπινης | |
CY1124617T1 (el) | Ενωσεις βενζολιου υποκατεστημενες με αρυλιο ή ετεροαρυλιο | |
CY1124891T1 (el) | Pd-1/pd-l1 αναστολεις | |
CY1123957T1 (el) | Θεραπεια συνδυασμου για καρκινο | |
CY1123606T1 (el) | Συζευγματα αντισωματων που εχουν τροποποιηθει με κυστεϊνη | |
CY1123595T1 (el) | Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 | |
TW201613930A (en) | Cytotoxic benzodiazepine derivatives | |
CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
CY1121390T1 (el) | Πυρρολοβενζοδιαζεπινες και συζευγματα αυτων | |
CY1121517T1 (el) | Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib | |
CY1120581T1 (el) | Ενωσεις και μεθοδοι χρησης τους | |
CY1119510T1 (el) | Συνδυασμος dr5 αγωνιστη και anti-pd1 ανταγωνιστη και μεθοδοι χρησης | |
CY1122478T1 (el) | Συνθεσεις που περιεχουν anti-cd38 αντισωματα και λεναλιδομιδη | |
CY1122721T1 (el) | Αντισωματα που δεσμευουν αχl | |
CY1121985T1 (el) | Ρυθμιστες πρωτεοστασης | |
EA201691421A1 (ru) | Гетероарилы и их применение | |
EA201700464A1 (ru) | Производные майтанзиноида, их конъюгаты и способы использования | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
UY37487A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
EA201591509A1 (ru) | Ингибиторы cdc7 | |
UY34648A (es) | Amidas como inhibidores de pim | |
UY33925A (es) | Inhibidores tricíclicos de quinasas | |
DOP2014000033A (es) | Aminoquinazolinas como inhibidores de quinasa | |
CY1122813T1 (el) | Διαλυτος cd33 για την αγωγη μυελοδυσπλαστικων συνδρομων (μds) |